CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2025.
Drug data last refreshed 2h ago · AI intelligence enriched 2h ago
CARBON DIOXIDE, USP is an inhaled gas product approved by the FDA as an X-ray contrast agent. It functions through X-ray contrast activity to enhance radiological imaging. This is a specialized diagnostic tool rather than a therapeutic agent.
Early-stage launch product with moderate competitive pressure (30%) suggests active commercial build-out and opportunity for cross-functional team growth.
X-Ray Contrast Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Despite zero current linked jobs, this newly approved diagnostic product for Martin Pharmaceuticals presents career opportunities in launch commercialization and market development. Early-stage launch roles in sales, marketing, and medical education will be critical as the company builds market presence in diagnostic imaging.